AU2010355523B2 - MLK4 gene, a new diagnostic and prognostic marker in cancers - Google Patents

MLK4 gene, a new diagnostic and prognostic marker in cancers Download PDF

Info

Publication number
AU2010355523B2
AU2010355523B2 AU2010355523A AU2010355523A AU2010355523B2 AU 2010355523 B2 AU2010355523 B2 AU 2010355523B2 AU 2010355523 A AU2010355523 A AU 2010355523A AU 2010355523 A AU2010355523 A AU 2010355523A AU 2010355523 B2 AU2010355523 B2 AU 2010355523B2
Authority
AU
Australia
Prior art keywords
mlk4
gene
expression
kras
vitro diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010355523A
Other languages
English (en)
Other versions
AU2010355523A1 (en
Inventor
Alberto Bardelli
Miriam Martini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2010355523A1 publication Critical patent/AU2010355523A1/en
Application granted granted Critical
Publication of AU2010355523B2 publication Critical patent/AU2010355523B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010355523A 2010-06-15 2010-06-15 MLK4 gene, a new diagnostic and prognostic marker in cancers Ceased AU2010355523B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/052684 WO2011158061A1 (en) 2010-06-15 2010-06-15 Mlk4 gene, a new diagnostic and prognostic marker in cancers

Publications (2)

Publication Number Publication Date
AU2010355523A1 AU2010355523A1 (en) 2013-01-10
AU2010355523B2 true AU2010355523B2 (en) 2014-09-11

Family

ID=43086697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010355523A Ceased AU2010355523B2 (en) 2010-06-15 2010-06-15 MLK4 gene, a new diagnostic and prognostic marker in cancers

Country Status (6)

Country Link
US (1) US9127319B2 (https=)
EP (1) EP2582837A1 (https=)
JP (1) JP2013528394A (https=)
AU (1) AU2010355523B2 (https=)
CA (1) CA2804335A1 (https=)
WO (1) WO2011158061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861239B1 (en) * 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
US20070037150A1 (en) * 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
WO2005095631A2 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005095637A1 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 beta (mlk4 beta)
ES2426814T3 (es) 2007-03-13 2013-10-25 Amgen Inc. Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bardelli A. Alterazioni genetiche e analisi funzionale della proteina chinasi MLK4 nei tumori umani. OSIRIS - Centro di Documentazione e Condivisione delle Conoscenze. 2009 *
Martini M et al. MLK4, a novel oncogenic kinase in the RAS pathway. SIBBM Seminar "Frontiers in Molecular Biology", Padua, 3-5 June 2010, P26. *

Also Published As

Publication number Publication date
JP2013528394A (ja) 2013-07-11
EP2582837A1 (en) 2013-04-24
US20130136755A1 (en) 2013-05-30
CA2804335A1 (en) 2011-12-22
AU2010355523A1 (en) 2013-01-10
WO2011158061A1 (en) 2011-12-22
US9127319B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
Zhou et al. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death
Tu et al. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Cipriano et al. FAM83B mediates EGFR-and RAS-driven oncogenic transformation
Ruiz et al. JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
AU2013226323B2 (en) Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status
US12343341B2 (en) Synthetic lethality and the treatment of cancer
US20040005615A1 (en) Amplification and overexpression of oncogenes
BR112013003506B1 (pt) Método para detectar a presença de uma isoforma de bard1 e método para discriminar câncer
US20030148341A1 (en) Gene amplification and overexpression in cancer
Talbot et al. Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival
CN107148481A (zh) 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法
AU2010355523B2 (en) MLK4 gene, a new diagnostic and prognostic marker in cancers
US20030175763A1 (en) Identification of an amplified gene and target for drug intervention
US20050026194A1 (en) Gene amplification and overexpression in cancer
WO2011129427A9 (ja) 癌の診断剤および治療剤
US20060141454A1 (en) Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
US20030092042A1 (en) Amplified oncogenes and their involvement in cancer
Shao et al. Upregulation of has_circ_0008389 promotes esophageal squamous cell carcinoma progression via miR-761 sponging and P2RY2 mRNA stabilization
WO2012034076A2 (en) Etv1 as a diagnostic, prognostic and therapeutic target for gastrointestinal stromal tumors
JP2018164442A (ja) 皮膚有棘細胞癌の判定、予防又は治療方法
US20030099985A1 (en) Amplified gene involved in cancer
KR101793174B1 (ko) Golgb1 또는 sf3b3을 이용한 재발암의 진단방법 및 golgb1 또는 sf3b3의 억제제를 함유하는 재발암 치료용 조성물
CN117462683A (zh) Eif3h在结直肠癌治疗中的应用
WO2010135411A2 (en) Aurora-a copy number and sensitivity to inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired